

# Hannah H Harrison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2420713/publications.pdf>

Version: 2024-02-01

18  
papers

1,480  
citations

567144

15  
h-index

839398

18  
g-index

20  
all docs

20  
docs citations

20  
times ranked

2869  
citing authors

#	ARTICLE	IF	CITATIONS
1	The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer. <i>PLoS ONE</i> , 2020, 15, e0236187.	1.1	20
2	A role for CBF $\beta$ in maintaining the metastatic phenotype of breast cancer cells. <i>Oncogene</i> , 2020, 39, 2624-2637.	2.6	11
3	Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways. <i>Molecular Oncology</i> , 2019, 13, 1693-1705.	2.1	15
4	The RUNX Transcriptional Coregulator, CBF $\beta$ , Suppresses Migration of ER+ Breast Cancer Cells by Repressing ER $\beta$ -Mediated Expression of the Migratory Factor TFF1. <i>Molecular Cancer Research</i> , 2019, 17, 1015-1023.	1.5	10
5	Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion. <i>Breast Cancer Research</i> , 2018, 20, 137.	2.2	39
6	HIF1-alpha expressing cells induce a hypoxic-like response in neighbouring cancer cells. <i>BMC Cancer</i> , 2018, 18, 674.	1.1	16
7	Tissue Factor promotes breast cancer stem cell activity <i>in vitro</i> . <i>Oncotarget</i> , 2017, 8, 25915-25927.	0.8	16
8	Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , 2015, 6, 4585-4601.	0.8	55
9	Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition. <i>Oncotarget</i> , 2014, 5, 11029-11037.	0.8	181
10	Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. <i>Breast Cancer Research</i> , 2013, 15, R21.	2.2	82
11	Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway. <i>Clinical Cancer Research</i> , 2013, 19, 3881-3893.	3.2	63
12	Contrasting Hypoxic Effects on Breast Cancer Stem Cell Hierarchy Is Dependent on ER $\beta$ Status. <i>Cancer Research</i> , 2013, 73, 1420-1433.	0.4	56
13	A Detailed Mammosphere Assay Protocol for the Quantification of Breast Stem Cell Activity. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2012, 17, 111-117.	1.0	299
14	Dickkopf1 Regulates Fate Decision and Drives Breast Cancer Stem Cells to Differentiation: An Experimentally Supported Mathematical Model. <i>PLoS ONE</i> , 2011, 6, e24225.	1.1	28
15	Disruption of a Quorum Sensing mechanism triggers tumorigenesis: a simple discrete model corroborated by experiments in mammary cancer stem cells. <i>Biology Direct</i> , 2010, 5, 20.	1.9	36
16	Irradiated Blm-deficient mice are a highly tumor prone model for analysis of a broad spectrum of hematologic malignancies. <i>Leukemia Research</i> , 2010, 34, 210-220.	0.4	11
17	Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor. <i>Cancer Research</i> , 2010, 70, 709-718.	0.4	468
18	Breast Cancer Stem Cells: Something Out of Notching?. <i>Cancer Research</i> , 2010, 70, 8973-8976.	0.4	74